Insights
Search Results
Alerts
7.29.26
Back-to-Back Executive Orders Shape the U.S. Quantum Agenda: What Founders and Investors Need to Know
On June 22, 2026, the administration issued two Executive Orders: Executive Order 14413, Ushering in the Next Frontier of Quantum Innovation (Quantum Innovation Executive Order) and Executive Order 14412, Securing the Nation Against Advanced Cryptographic Attacks (Post-Quantum Cryptography Executive Order). Together, the Executive Orders reinforce the federal government’s long-term commitment to quantum information science and technology (QIST) while continuing to frame quantum as both an economic and national security priority. Although they impose relatively few immediate legal obligations on most companies, the Executive Orders provide important signals about where federal investment, procurement, and strategic partnerships are likely to emerge over the coming years.
Alerts
7.23.26
Health Reimbursement Signals: CMS Proposes Payment Frameworks for “Software as a Medical Service”
On July 2, 2026, the Centers for Medicare and Medicaid Services (CMS) released the calendar year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule and on July 14, 2026, subsequently released the CY 2027 Physician Fee Schedule (PFS) proposed rule.1 These proposed rules establish a newly named Medicare payment category, Software as a Medical Service (SaMS), for software that supports clinical decision-making through algorithmic analysis.2 This is CMS’ first effort to pay for software-based clinical services in a structural way as their own category rather than as a cost buried inside reimbursement for another procedure. The consequential impact is that CMS would create a new reimbursement vehicle for software and AI-enabled products to be reimbursed as standalone services in the future. The proposal is worth close attention from stakeholders because Medicare reimbursement often determines the success of software or AI products intended for clinical purposes. Comments are due August 31, 2026, on the OPPS rule and September 14, 2026, on the PFS rule.
Client Highlights
7.21.26
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch
On July 20, 2026, Freenome Holdings, Inc. (Freenome), an early cancer detection company developing blood-based screening tests, announced the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (PCSC). The combined company is renamed Freenome, Inc., and its common stock commenced trading on the Nasdaq Capital Market on July 21, 2026, under the new ticker symbol “FRNM.” Wilson Sonsini Goodrich & Rosati advised Freenome on IP matters related to the transaction.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Client Highlights
1.27.26
Wilson Sonsini Advises Genyro on License Agreement with Caltech for “Sidewinder” Technology
On January 26, 2026, Genyro Inc., an early-stage, California-based biotechnology company advancing next-generation DNA construction, announced that it has entered into an exclusive licensing agreement with the California Institute of Technology (Caltech) for Sidewinder™, a breakthrough DNA construction invention recently featured in Nature. Wilson Sonsini Goodrich & Rosati advises Genyro on IP and corporate matters and represented the company in the licensing agreement with Caltech.
Sidewinder represents the first DNA construction technology based on DNA 3-Way Junctions (3WJ), enabling the accurate construction of long, complex, and highly repetitive DNA sequences that have historically been challenging to build. The technology was developed by Professor Kaihang Wang, tenure-track assistant professor of biology and biological engineering at Caltech and co-founder and chief scientific advisor at Genyro. It is the first DNA construction method to separate the sequence information of the final assembled DNA product from the information guiding its assembly.
The Wilson Sonsini team advising Genyro includes Karen Deschaine, Lou Lieto, and Nellie Brutocao.
For more information, please see Genyro’s news release. Additional coverage of Genyro is available in The Times and Endpoints News.
Sidewinder represents the first DNA construction technology based on DNA 3-Way Junctions (3WJ), enabling the accurate construction of long, complex, and highly repetitive DNA sequences that have historically been challenging to build. The technology was developed by Professor Kaihang Wang, tenure-track assistant professor of biology and biological engineering at Caltech and co-founder and chief scientific advisor at Genyro. It is the first DNA construction method to separate the sequence information of the final assembled DNA product from the information guiding its assembly.
The Wilson Sonsini team advising Genyro includes Karen Deschaine, Lou Lieto, and Nellie Brutocao.
For more information, please see Genyro’s news release. Additional coverage of Genyro is available in The Times and Endpoints News.
Alerts
1.22.26
2026 Antitrust Year in Preview
Last year was a landmark in the development of antitrust law. Enforcers, legislators, and private parties grappled with the fundamental shift represented by artificial intelligence (AI) technologies, the resolution of important digital technology antitrust cases, and significant divergence in policy across a presidential administration transition. The changes will not stop in 2026. In this preview, we focus on several economic sectors that were most impacted by developments in antitrust law in 2025 to identify the trends that will drive governmental and private activity in antitrust in 2026.
Client Highlights
12.15.25
Wilson Sonsini Advises Quantum Computing on $110 Million Acquisition of Luminar Semiconductor
On December 15, 2025, Quantum Computing (QCi), an innovative, quantum optics and integrated photonics technology company, announced that it has signed an agreement to acquire Luminar Semiconductor (LSI), a wholly owned subsidiary of Luminar Technologies, in an all-cash transaction valued at $110 million, subject to customary adjustments. Wilson Sonsini Goodrich & Rosati is advising QCi on the transaction
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.